leisure time -WSS

leisure time

author：leisure time 2025-09-30 23:40:19 - browse：682

An effective treatment for Alzheimer’s disease has long been a holy grail in the pharmaceutical industry. In early June, some hope appeared when the FDA agreed that the anti-amyloid antibody lecanemab (to be sold by Eisai as Leqembi) outperformed placebo in trials. It is expected to receive full approval by July 6.

But this may not necessarily be purely good news.

On the latest episode of the “First Opinion Podcast,” physician and professor Jason Karlawish argues that lecanemab and other promising new drugs, such as donanemab, will introduce complicated issues into the field of Alzheimer’s care. These medications require a great deal of testing and patient monitoring, trained physicians, and other resources in a system that is already stretched thin.

“Dr. Karlawish’s dream of reason would be … a training module for physicians to learn the key things they need to learn and then self-assess their comfort with the drug,” Karlawish said. “But that’s Karlawish’s dream of reason in a world that seems increasingly less reasonable sometimes.”

Karlawish is a professor of medicine, medical ethics and health policy, and neurology at the University of Pennsylvania’s Perelman School of Medicine. The conversation is based off his recent First Opinion, “The FDA needs a risk evaluation and mitigation strategy for Alzheimer’s drug lecanemab.“

Be sure to sign up for the weekly “First Opinion Podcast” on Apple Podcasts, Stitcher, Google Play, or wherever you get your podcasts.

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： Study on Amgen’s bispecific immunotherapy produces positive data

focus

WSS

Medicare’s new pay boost for primary care is angering specialists

Results on Novartis prostate cancer therapy could expand its use

Why a market frenzy over new weight loss drugs defies logic

STAT Summit: The economic case for universal basic health care

Weight loss drugs should be covered by insurers, AMA says

Weight loss drugs should be covered by insurers, AMA says

hotspot

leisure time

hotspot

Drug repurposing or repositioning? The language matters

The problems with dementia villages

Medical leaders decry Supreme Court decision on affirmative action

J&J lung cancer data amount to new salvo against AstraZeneca

The high cost of giving birth even with insurance

UnitedHealth, Optum discontinue NaviHealth name

George Santos makes 1st court appearance after pleading not guilty to 13 counts

What health policies could hitch a ride on a spending bill?

Alkermes shareholders re

NIH chief: government has fallen behind pharma on clinical trials

explore

NIH chief: government has fallen behind pharma on clinical trials

NIH chief: government has fallen behind pharma on clinical trials

The problems with dementia villages

Questions loom on AstraZeneca cancer drug as safety concerns ebb

Experimental asthma app from Apple and Anthem shows promise

Ventyx halts psoriasis drug development after lackluster trial results

focus

focus

focus

focus